
usd apr pm et
summari compani one largest pharmaci world
store mainli
price-to-earnings oper ep
risk assess reflect compani strong
market share posit rel stabl retail
drug industri partli off-set growth non-tradit
competitor potenti advers legisl
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
still uncertain impact
greater macroeconom slowdown
wba result forecast wba
gener retail busi total net sale
hurt especi
discretionari categori beauti
gener merchandis pharmaci sale
total net sale like less impact
given natur product
wba decis waiv deliveri fee
elig prescript howev expect
see volatil prescript sale mani
health provid current give
wba busi total net sale
expos retail sale versu pharmaci
sale like feel greatest pressur
current macro situat close
nearli optician hear care store
 store anoth sale
headwind go forward howev cut
cost furlough employe
outbreak persist expect
liber area choos cut
pull fy guidanc fiscal
earn releas due
maintain hold rate larg due
valuat current trade forward
price-to-earnings steep discount
five-year mean yet concern
long-term structur pressur
impact global econom slowdown
furthermor presidenti elect
could result volatil share
sinc candid push major
reform health care particularli
come prescript drug price caution
investor seek purchas share
beneficiari outbreak
opinion impact
net neg impact financi
retail sale consum stockpil due
partnership gener drug save
payoff one compani mani
on-going reimburs pressur
longer-than-expect period consum
quarantin lockdown
target fy
ep estim steep discount
five-year forward mean
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut chairman
corpor overview inc one market leader retail
pharmaci sale billion fy along compani equiti
method invest presenc countri employ peopl
total fy sale europ exclud
rest world
wba portfolio brand includ walgreen duan read boot allianc healthcar well
increasingli global health beauti product brand soap glori liz earl botan sleek
make-up yourgoodskin
wba oper organ three divis also report segment
retail pharmaci usa fy total sale consist locat retail store fy
market leader approxim popul within
five-mil radiu walgreen duan read acquir retail pharmaci compon
segment pharmaci sale prescript drug retail sale health care retail
product includ non-prescript drug beauti toiletri gener merchandis fy
pharmaci compon sale retail compon sale fill
million prescript billion adjust equival fy sale
reimburs receiv manag care organ government agenc pharmaci benefit
manag pbm compani privat insur fy pharmaci sale
retail pharmaci intern fy total sale consist pharmacy-l health beauti
retail busi eight countri oper retail store divis fy
princip retail pharmaci brand boot thailand norway republ ireland
netherland benavid mexico ahumada chile fy pharmaci portion divis
compris total sale retail portion compris total sale
divis focus retail sale compar divis focus
pharmaci sale
pharmaceut wholesal fy total sale oper allianc healthcar brand
suppli medicin health care product relat servic pharmaci
doctor health center hospit year distribut center countri primarili
europ fy
corpor strategi unlik competitor health corpor
activ seek becom increasingli vertic integr health care compani instead
place greater emphasi strateg partnership joint ventur evidenc partnership
labcorp among other also
evidenc number equiti method invest made largest equiti
method invest approxim total carri valu equiti method invest
ownership equiti method invest includ pharmaceut compani china option
lead home infus servic provid
impact major develop march compet acquisit
store billion initi agreement took place june agre sell
drugstor billion cash howev due concern feder trade
commiss fewer store sold
 rumor novemb bloomberg report kkr co prepar propos
take privat kkr histori make mega-buyout deal especi late econom cycl
success think deal could valu requir cash
debt make largest lbo histori one hand take privat make sens sinc
compani midst major cost manag program take compani privat
probabl deliv cost save origin plan quicker pace also drug
retail industri current major transform evidenc rise new competit
non-tradit busi model amazon pillpack servic converg among valu chain
 acquir aetna emphas partnership acquisit hope
one pilot eventu provid signific upsid go privat could cultiv
relationship method without watch eye sharehold hand find
deal extrem riski given size deal regulatori scrutini face health care sector today
question surround longev wba oper model
financi trend fy total sale increas constant-curr adjust oper
incom decreas constant-curr adjust ep decreas even though
share repurchas contribut percentag point ep growth
june board approv new stock repurchas program author repurchas
billion common stock repurchas program expir date fy expect
repurchas billion worth share lower billion share repurchas
fy
balanc sheet solid fy net debt-to-ebitda ratio current offer
dividend yield
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
under-valued usd
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neg fundament outlook
drug retail sub-industri next month
long term posit outlook
part due age overal popul
increas life expect increas
avail gener drug continu
develop innov drug increas
number individu health
insur howev next month
see certain factor imped growth
non-tradit player declin
front-end retail sale due chang
retail pharmaci industri reli heavili
privat government third-parti payer
reimburs prescript drug sold
pharmaci consum
payer take action restrict elig
reduc price reimburs rate sale
margin retail pharmaci industri
neg impact weve seen phenomenon
play recent year especi sinc
signific consolid health
care sector given bargain
power player higher valu chain
pharmaci benefit manag pbm
reimburs pressur noth new
sub-industri howev new view
less opportun mitig headwind
exampl retail pharmaci use benefit
lower price paid procur gener
drug sale drug typic carri
higher margin pharmaci prefer sell
drug brand one howev recent
weve seen decreas gener drug deflat
 higher price paid drug retail
increas reimburs pressur lower
gener drug price deflat lead margin
contract next month
late front-end store sale drug
retail also pressur
anoth miss opportun counter
pressur relat reimburs rate
see retail sale continu pressur
consum habit dynam chang
on-line channel therebi result
less foot traffic insid drug store also
 economi current late stage
econom cycl econom downturn
could neg impact front-end
predict acceler consolid
converg health care industri
would allevi reimburs
pressur third-parti payer also
make sens competit landscap
perspect industri becom
fragment small competitor
competitor non-tradit busi
drive scale effici
time battl growth key
determin whether drug retail
abl sustain industry-rel
drug retail sub-industri
vs broader
consum stapl sector
drug retail sub-industri
vs
broader consum stapl sector
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
pm et cfra maintain hold opinion share walgreen boot
allianc inc cut target
fy ep estim steep discount wba five-year forward
mean lower fy ep estim fy
post fiscal adj-ep vs
consensu constant currenc sale grew
quarter end march saw signific spike
sale first day saw sale take sharp turn last
day quarantin impos consum stockpil effect
began taper expect wba retail busi total sale
suffer especi discretionari categori beauti
gener merchandis longer quarantin effect
today earn call seem commit maintain current
capit alloc strategi howev think share repurchas could
tabl shutdown persist june /arun sundaram cfa
et cfra maintain hold opinion share
inc keep target fy aug ep
estim steep discount mean justifi
view long-term structur pressur within retail pharmaci includ
disrupt non-tradit player like amazon pillpack servic
also discount difficult market condit dont seem
improv rais fy ep estim fy
post adj-ep vs
consensu attribut beat benefit share repurchas
reimburs pressur continu sever impact margin
adj-oper incom retail pharmaci usa segment front-end
retail comp sale improv still declin due
de-emphasi tobacco product maintain hold due current valuat
think much work order get ahead market trend /arun
et cfra reiter hold opinion share walgreen boot
allianc inc lower target price base
fy ep aug estim steep late-cycl discount
forward mean justifi heavi reimburs pressur weak
market condit lower fy ep estim fy
post feb-q ep vs
consensu comp sale retail pharmaci usa segment grew
fell segment lower fy ep guidanc
growth flat growth acknowledg difficult
quarter sinc headwind note quarter entir new
opportun mitig headwind believ led weak
result less sever cough/flu season go forward expect
pressur subsid acceler action plan newli
announc leadership structur given current valuat see limit
et cfra maintain hold opinion share walgreen boot
allianc inc keep target fy
ep estim steep discount wba five-year mean
justifi industry-wid headwind challeng market heighten
risk miss fy target weak fiscal lower fy
ep estim fy
post fiscal adj-ep vs consensu
attribut much miss weak prescript sale comp script
sale grew expect growth howev state dec
script sale rang due strong cold flu season
share may seem cheap maintain hold due tough expect macro
environ low visibl wba pilot program start
pay drug retail busi model chang chang bring
opportun unsur whether appropri posit
futur success arun sundaram cfa
et cfra maintain hold recommend share walgreen
allianc inc per bloomberg kkr consid take
privat success think deal could valu
cash debt one hand take privat make sens sinc compani
midst major cost manag program take compani
privat probabl deliv cost save origin
plan quicker pace also drug retail landscap current
transform evidenc rise non-tradit model
amazon pillpack converg among valu chain cvs-aetna
merger emphas partnership acquisit hope
one pilot take go privat could cultiv
relationship method without watch eye sharehold
hand find deal extrem riski given size current
stage credit cycl challeng regulatori environ
et cfra reiter hold opinion share walgreen boot
allianc inc keep target fy
aug ep estim discount five-year mean justifi
industry-wid headwind challeng market lower fy
ep estim begin fy post fiscal
adj-ep vs consensu fiscal
overal good quarter rel weak first half perform
comp prescript volum grew vs
yet ep growth mute increas invest lap
benefit fy guid flat ep growth core growth share
repurchas off-set higher bonu accrual tax rate
navig challeng macro environ focus cost save
increas invest fuel long-term capabl hope one
mani pilot program provid signific upsid next coupl
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
